Crescent Biopharma (CBIO) Total Non-Current Liabilities (2015 - 2024)
Crescent Biopharma (CBIO) posted quarterly Total Non-Current Liabilities of $47.1 million for Q4 2024, up 582.35% year-over-year from $6.9 million in Q1 2024, and up 989.72% quarter-over-quarter from $4.3 million in Q3 2024.
Crescent Biopharma (CBIO) Total Non-Current Liabilities (2015 - 2024) Analysis & Trends
Crescent Biopharma (CBIO) has reported Total Non-Current Liabilities for 10 consecutive years, with $47.1 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Total Non-Current Liabilities rose 582.35% year-over-year to $47.1 million; the TTM figure through Dec 2024 stood at $47.1 million (up 582.35% YoY), while the FY2024 annual figure was $47.1 million, up 582.35% from the prior year.
- Total Non-Current Liabilities improved to $47.1 million in Q4 2024 per CBIO's latest filing, from $4.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $47.1 million in Q4 2024 and bottomed at $4.3 million in Q3 2024.
- Historically, Total Non-Current Liabilities has averaged $11.4 million across 5 years, with a median of $10.1 million in 2021.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slumped 49.83% — and 2024, when it soared 582.35%.
- Crescent Biopharma's Total Non-Current Liabilities stood at $14.6 million in 2020, then retreated by 12.8% to $12.7 million in 2021, then plunged by 30.31% to $8.9 million in 2022, then decreased by 22.28% to $6.9 million in 2023, then jumped by 582.35% to $47.1 million in 2024.
- Business Quant data shows CBIO's Total Non-Current Liabilities at $47.1 million in Q4 2024, $4.3 million in Q3 2024, and $4.4 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 9.32 Bn |
| 10 | Crescent Biopharma | 1.09 Bn | 921.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 47.10 Mn |
| Sep 30, 2024 | 4.32 Mn |
| Jun 30, 2024 | 4.36 Mn |
| Mar 31, 2024 | 5.29 Mn |
| Dec 31, 2023 | 6.90 Mn |
| Sep 30, 2023 | 6.65 Mn |
| Jun 30, 2023 | 7.02 Mn |
| Mar 31, 2023 | 6.74 Mn |
| Dec 31, 2022 | 8.88 Mn |
| Sep 30, 2022 | 7.84 Mn |
| Jun 30, 2022 | 9.32 Mn |
| Mar 31, 2022 | 13.43 Mn |
| Dec 31, 2021 | 12.74 Mn |
| Sep 30, 2021 | 10.84 Mn |
| Jun 30, 2021 | 11.68 Mn |
| Mar 31, 2021 | 12.52 Mn |
| Dec 31, 2020 | 14.61 Mn |
| Sep 30, 2020 | 11.97 Mn |
| Jun 30, 2020 | 12.60 Mn |
| Mar 31, 2020 | 13.22 Mn |